- Report
- March 2024
- 191 Pages
Global
From €3259EUR$3,374USD£2,787GBP
€3621EUR$3,749USD£3,097GBP
- Report
- September 2023
- 140 Pages
Global
From €5747EUR$5,950USD£4,915GBP
- Report
- March 2024
- 200 Pages
Global
From €4009EUR$4,150USD£3,428GBP
- Report
- February 2024
- 115 Pages
Global
From €4588EUR$4,750USD£3,923GBP
- Report
- December 2023
- 120 Pages
Global
From €5747EUR$5,950USD£4,915GBP
- Report
- May 2023
- 142 Pages
Global
From €2414EUR$2,499USD£2,064GBP
- Report
- February 2024
- 115 Pages
Global
From €4588EUR$4,750USD£3,923GBP
- Report
- March 2018
- 100 Pages
United States
From €2318EUR$2,400USD£1,982GBP
- Report
- January 2023
- 155 Pages
United States
From €5747EUR$5,950USD£4,915GBP
- Report
- February 2023
- 150 Pages
United States
From €2405EUR$2,490USD£2,057GBP
- Report
- November 2023
- 86 Pages
Global
From €3500EUR$3,881USD£3,098GBP
- Report
- November 2023
- 160 Pages
Global
From €2897EUR$2,999USD£2,477GBP
The Cancer Biopsy market within the In Vitro Diagnostics (IVD) industry is a rapidly growing sector. It is used to detect and diagnose cancer in patients, and is a key component of the IVD industry. Cancer biopsy tests are used to detect the presence of cancer cells in a sample of tissue taken from the patient. The sample is then analyzed to determine the type and stage of cancer. The results of the biopsy can help guide treatment decisions.
The Cancer Biopsy market is driven by the increasing prevalence of cancer, advances in technology, and the growing demand for early diagnosis and treatment. The market is expected to continue to grow in the coming years, as more advanced tests become available and the demand for early diagnosis and treatment increases.
Some of the major companies in the Cancer Biopsy market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more
